clarus_final_indentity.jpg
Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial
26 juin 2017 08h30 HE | Clarus Therapeutics, Inc.
NORTHBROOK, Ill., June 26, 2017 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for JATENZO™ (formerly Rextoro™), the Company’s...
clarus_final_indentity.jpg
Clarus Therapeutics Provides Update on Patent Infringement Lawsuit Against Lipocine’s Oral Product for Testosterone Replacement Therapy
13 oct. 2016 08h30 HE | Clarus Therapeutics, Inc.
Court dismissed lawsuit due to lack of FDA approval for LPCN-1021 and not on merits of case Clarus will be allowed to refile its lawsuit, if necessary NORTHBROOK, Ill., Oct. 13, 2016 (GLOBE...
clarus_final_indentity.jpg
Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy
17 mai 2016 08h30 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., May 17, 2016 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of JATENZOTM, its...
clarus_final_indentity.jpg
Clarus Therapeutics Submits New Drug Application for Rextoro (formerly CLR-610) for the treatment of Low Testosterone
13 janv. 2014 09h00 HE | Clarus Therapeutics Holdings, Inc.
Northbrook, Ill, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the submission of a New Drug Application (NDA) for Rextoro™ (formerly CLR-610), the Company's oral...
clarus_final_indentity.jpg
Clarus Therapeutics Presents at 32nd Annual J.P. Morgan Healthcare Conference
09 janv. 2014 10h00 HE | Clarus Therapeutics Holdings, Inc.
Northbrook, Ill, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that Robert E. Dudley, Ph.D., chief executive officer of Clarus Therapeutics will present an update on the...
clarus_final_indentity.jpg
Clarus Therapeutics Bolsters Executive Team with Addition of Chief Medical and Chief Scientific Officers
01 juil. 2013 08h00 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, July 1, 2013 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the hiring of Theodore M. Danoff, M.D., Ph.D. and Wael A. Salameh, M.D., FACP to fill the newly created...
clarus_final_indentity.jpg
Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint
25 sept. 2012 08h00 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today reported top-line results from the Company's ongoing Phase 3 study of CLR-610, the Company's proprietary oral...
clarus_final_indentity.jpg
Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
19 sept. 2012 08h00 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...
clarus_final_indentity.jpg
Clarus Therapeutics Appoints Bela S. Denes, M.D. as Chief Medical Officer
21 juin 2012 08h00 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, June 21, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of Bela S. Denes, M.D. to the newly created role of chief medical officer. Dr. Denes was...
clarus_final_indentity.jpg
Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy
01 mai 2012 08h22 HE | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that patient enrollment has been completed in the Company's pivotal Phase 3 clinical trial of...